Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $5.49, but opened at $5.84. Recursion Pharmaceuticals shares last traded at $5.66, with a volume of 13,199,634 shares trading hands.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on RXRX. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Morgan Stanley dropped their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $7.60.
Get Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Up 1.4%
The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a fifty day simple moving average of $4.81 and a 200-day simple moving average of $6.35. The firm has a market cap of $2.26 billion, a P/E ratio of -3.62 and a beta of 0.84.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.39) EPS. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of RXRX. Man Group plc bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $479,000. Rockefeller Capital Management L.P. boosted its position in Recursion Pharmaceuticals by 323.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company's stock worth $1,906,000 after purchasing an additional 215,283 shares during the period. Invesco Ltd. lifted its holdings in shares of Recursion Pharmaceuticals by 54.6% in the 4th quarter. Invesco Ltd. now owns 178,619 shares of the company's stock worth $1,207,000 after acquiring an additional 63,068 shares during the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $23,429,000. Finally, Northern Trust Corp lifted its stake in shares of Recursion Pharmaceuticals by 18.4% in the 4th quarter. Northern Trust Corp now owns 2,394,511 shares of the company's stock worth $16,187,000 after purchasing an additional 371,886 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
